| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Inventory | 4,126,716 | |||
| Prepaid expenses and other current assets | 6,317,332 | |||
| Cash and cash equivalents | 8,900,814 | |||
| Accounts receivable | 1,751,422 | |||
| Total current assets | 21,096,284 | |||
| Other assets | 464,388 | |||
| Operating lease right-of-use assets, net | 238,266 | |||
| Equity method investment | 592,602 | |||
| Total assets | 22,391,540 | |||
| Accrued expenses | 5,313,670 | |||
| Current portion of operating lease liabilities | 56,560 | |||
| Current portion of unsecured convertible promissory note | 14,000,000 | |||
| Income taxes payable | 1,856,629 | |||
| Accounts payable | 10,262,137 | |||
| Total current liabilities | 31,488,996 | |||
| Unsecured convertible promissory note | 20,437,000 | |||
| Warrant liability | 7,451,124 | |||
| Operating lease liabilities | 204,145 | |||
| Total liabilities | 59,581,265 | |||
| Accumulated deficit | -592,416,994 | |||
| Common stock, par value 0.01 per share 260,000,000 shares authorized 43,479,051 and 23,905,635 shares issued and outstanding at june 30, 2025 and september 30, 2024, respectively | 434,791 | |||
| Additional paid-in capital | 554,792,478 | |||
| Total stockholders' deficit | -37,189,725 | |||
| Total liabilities and stockholders' deficit | 22,391,540 | |||
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)